Navigation Links
Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced
Date:12/3/2009

though there is no cure for ADHD, there are accepted treatments that specifically target its symptoms. Standard treatments include educational approaches, psychological or behavioral modification, and medication.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's Web site: http://www.shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regu
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
2. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
3. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
4. Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
5. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
6. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
7. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
8. Panda Ethanols Hereford, Texas Subsidiary Files Voluntary Chapter 11
9. Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products
10. ETHEX Corporation Issues Nationwide Voluntary Recall of Products
11. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...   JOLT , a leading technology accelerator, announced today ... portfolio of startups. Next-level tech and boundary-pushing innovation have ... accelerator, and Cohort four is no exception, with six ... its launch in July 2012, JOLT has produced 17 ... at 23 investments, JOLT,s portfolio has an overall mix ...
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)...  David Hardison, Ph.D., vice president of health ... been elected chairman of the board for the ... to establish common protocols around the use of ... electronic health records. Hardison will ... organizations across the research and health care arena ...
(Date:7/28/2014)... 28, 2014 Immunomic Therapeutics, Inc. (ITI) ... further develop potential treatments for glioblastoma multiforme (GBM), the ... with their patented vaccine platform, LAMP-vax. , The ... based on the work of John H. Sampson, MD, ... Preston Robert Tisch Brain Tumor Center at Duke University ...
Breaking Biology Technology:JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4
... 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. ... contract research organization (CRO) that provides design, development, ... registries to many of the world,s leading pharmaceutical ... for the Second Annual Vaccine Industry Excellence Award ...
... service revenue of $264.5 million grows 7.8% year-over-year- ... of $0.25- Net quarterly book-to-bill ratio equates to ... PRXL ) today announced its financial ... 2009.For the three months ended March 31, 2009, ...
... Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC ... has secured rights to seven key patents from Company ... patents that will significantly enhance Sinobiopharma,s ability to execute ... to market.The patents are for the following:, ...
Cached Biology Technology:Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 2PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 3PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 4PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 5PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 6PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 7PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 8PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 9PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 10PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 11PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 12PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 13PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 14PAREXEL Reports Third Quarter Fiscal Year 2009 Financial Results 15Sinobiopharma Secures Rights to Seven Key Patents 2
(Date:7/28/2014)... fertility problems, many of these due to genetic factors. ... such genes, which reduce an individual,s ability to reproduce, ... Institute of Science that recently appeared in Nature ... only can it explain the high rates of male ... the causes of genetic diseases and their treatment. ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... CANCER RESEARCH UK scientists at Barts Cancer Institute have ... make cancer therapy significantly more effective, according to research ... at Barts Cancer Institute, part of Queen Mary University ... adhesion kinase (FAK), signals the body to repair itself ... damaging DNA. When the researchers removed FAK from blood ...
Breaking Biology News(10 mins):Mutations from Venus, mutations from Mars 2Dinosaurs fell victim to perfect storm of events, study shows 2New drug target can break down cancer's barrier against treatment 2
... Might those bacteria lead oil companies to change their methods ... same time reducing the carbon dioxide that burning oil and ... be possible. Larter, professor of geoscience and holder ... University of Calgary, was the keynote speaker today for the ...
... a firm link between environmental change and human disease ... a team of scientists from the University of Wisconsin-Madison, ... of the CDC journal Emerging Infectious Diseases, ... incidence of malaria to land-use practices in the Amazon. ...
... bacteria in seven species of sharks and redfish captured ... of these wild, free-swimming fish harbored several drug-resistant bacterial ... Journal of Zoo and Wildlife Medicine , found antibiotic-resistant ... also found multidrug-resistant bacteria in fish at nearly all ...
Cached Biology News:Incidence of malaria jumps when Amazon forests are cut 2Incidence of malaria jumps when Amazon forests are cut 3Wild sharks, redfish harbor antibiotic-resistant bacteria 2
... Fermentation System to achieve high ... and maximum information output 4 ... precision with small-scale requirements provides users ... with E.coli, Pichia pastoris, yeast, fungi ...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Antibody Binding: High, 400 ng IgG/cm ... , Binding Interaction: Hydrophobic/Ionic , Performance Certified: ... Flat , Maximum Well Volume: 360 µl ... ,Features, Special optically clear polystyrene ...
...
Biology Products: